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at local level; inadequate data collection and follow-up process at later stages of 
life; poor awareness of immunisation schedule by health care practitioners (HCPs); 
lack of structural and operational policies to promote and deliver vaccination 
at later stages of life; infrequent interactions with the health care system dur-
ing adult-hood; limited and inconsistent information dissemination by HCPs and 
government; negative messages on vaccination through media; complacent public 
attitude towards the risk posed by vaccine preventable diseases. ConClusions: 
Three main domains of barriers exist: low institutional facilitation to recommend 
lifespan immunisation as part of NIP; inadequate mechanisms at regional and local 
level to facilitate citizen access to immunisation / vaccination; low patient demand 
for immunisation at older stages of life. To overcome these barriers a broad-ranging 
approach based on awareness is required, which includes providing comprehensive 
pharmacoeconomic evidence to policy makers and payers, developing information 
tracking systems that enable follow up, and HCP education to facilitate informa-
tion dissemination.
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objeCtives: The topicality of septic complications (SC) in early period after surgery 
reminds very high despite the antibiotic prophylaxis. The prediction of SC can be 
provided by ATA-test (DTE index) by the registration the structural and functional 
changes of serum albumin. Methods: Prospective observational controlled study 
of typical practice for cancer patients. Inclusion criteria: cancer patients; age – 
over 18 years; major operations. Exclusion criteria: inflammation diseases during 
3 months before surgery; extended operations on pancreas, liver and bile ducts; 
renal and/or hepatic failure. ATA-test was made ones a day during 7 days in patients 
without SC, 14 days – with SC. Data about direct medical costs was collected via 
medical charts. Analysis was performed with methods of descriptive statistic, para-
metric and non-parametric criteria. Results: Data on 104 patients were obtained: 
11 had SC. Ratio (male:female) was 1:1,4. Average age – 61.2±12.5 years. Average 
level DTE in first 2 hours after surgery in patients with SC was 15.4±7.2%, without 
SC -31.8±14%, in case SC it didn’t increase till normal meanings (40-175%) during 
7 days. Direct medical cost of patient with SC – 8838$: 5352$ - cost for medicines, 
1949$- hospitalization during 36.5 days (7.5 days in ICU), 1537$-medical services; 
without SC – 2992$: 534$-medicines, 1309$-hospitalization during 30 days (3 days in 
ICU), 1149$-medical services. ConClusions: SC can be predicted by ATA-test (DTE 
index) in first hours after surgery. It provides economy in 10 times for medicines 
and in 3 times in common direct medical costs.
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objeCtives: Information on staff resource requirements for outpatient HIV care 
is useful for effective planning of the service, especially given the increasing and 
increasingly complex patient population. The aim of this study was to estimate 
the staff resources used in the HIV outpatient clinic in Cork University Hospital 
(CUH). Methods: Staff in the CUH HIV outpatient clinic completed time sheets 
for 6 consecutive clinics (March-April 2013). Patient identifiable data were not col-
lected, however basic patient characteristics (gender, route of transmission, age > 
50 years, Irish nationality, late diagnosis) and clinical information (type of visit and 
complexity) were included. Results: Over the study period 83% (127/153) of doctor 
visits were timed. 46% of patients were seen by a senior doctor. The average length 
of time spent with each patient by senior doctors was 14.5 minutes, while NCHDs 
spent an average of 24.1 minutes per patient. Patient gender, age, route of infection, 
nationality, late diagnosis and visit type had little impact on the average length of 
doctor visit, but visit length was affected by doctor type and complexity. In addition, 
clinical nurse specialists saw 62% of patients, and spent 14.3 minutes on average 
per patient. ConClusions: Time spent with patients varies with the experience 
level of the doctor. Visit length was also affected by the individual complexity of the 
visit. The results of this study will be fed into a wider study estimating the factors 
influencing the cost of providing ambulatory HIV care in Ireland.
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objeCtives: Increasingly, human immunodeficiency virus (HIV) infection is man-
aged as a chronic condition. Payers in the United States (US) typically manage 
chronic conditions as cost-effectively as possible. One element of cost containment 
is to institute policies driving utilization of less-expensive generic medications. 
As generic HIV drugs become available, concerns arise that “de-simplifying” HIV 
treatment by incentivizing use of generic components of fixed-dose combination 
(FDC) treatments will impact adherence, resulting in adverse treatment effects. 
This study evaluated US payers’ likelihood to incentivize patients/physicians from 
branded FDCs toward a combination of generic single-dose drugs. Methods: We 
conducted targeted research of published literature and payer Web sites to identify 
information relevant to HIV coverage polices. This informed a discussion guide 
for one-on-one interviews with 10 payers from US commercial health insurance 
companies. Participants were recruited to ensure diversity from organizational 
sizes and geographical regions; interviews were double-blinded (i.e., payer and 
pharma). Results: Payers indicated HIV management is increasingly perceived as 
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objeCtives: Evidence of a significant vaccine policy shift can be witnessed not only 
in the number of new vaccines available in Japan but also in the way vaccine policy 
is being formulated. In 2010, policy makers decided for the first time ever to commis-
sion economic analyses as a reference in their consideration of subsidy allocation. 
This research offers a firsthand account of the recent changes in vaccine policies 
by examining the decision-making process from the perspective of researchers 
for economic evaluations. Methods: In order to understand the vaccine policy-
making process, we analyzed all the documents that were distributed and dis-
cussed during the government committee meetings starting from February 2010 
when the revision of the Preventive Vaccination Law was initially proposed to May 
2012 when the final recommendations were made. We then created a time-series 
table to summarize the main issues of the discussions and final conclusions from 
official reports and other relevant information recorded in the minutes. Results: 
Economic evaluations were conducted for seven vaccines under consideration for 
the routine immunization program (Hib, PCV for children and adults, HPV, vari-
cella, mumps, hepatitis B). The findings suggested most of them were cost-effective 
options. However, for the Hib vaccine, the expected savings was less than the addi-
tional costs required (23.8 billion yen increased), and for the hepatitis B vaccine, 
the incremental cost-effectiveness ratio was far beyond the acceptable range (18.3 
million yen per QALY). Nevertheless, all the vaccines were equally recommended 
for inclusion in the routine immunization program. ConClusions: The findings 
included reasons why policy makers decided to commission economic evidence 
in the first place, the importance of external influences, the choice of evaluation 
methods, the extent to which policy makers actually incorporated the economic 
evidence into new vaccine policies, and the implications of using cost-effectiveness 
analyses on the future of Japanese health policy-making.
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objeCtives: Until recently, there has not been a global focus on getting hepatitis A 
vaccines on country policy agendas. Using a vaccine policy adoption framework, we 
sought to identify drivers and barriers of hepatitis A vaccine adoption in six coun-
tries. Methods: We applied a four-part framework to identify the public vaccine 
adoption process and drivers and barriers for hepatitis A vaccine adoption: 1) evidence 
in support of hepatitis A vaccine adoption; 2) existence of supportive policies; 3) politi-
cal priority of hepatitis A within the country; and 4) whether or not the stakeholders 
were empowered and willing to act. Data were collected using a qualitative policy 
survey and a systematic literature review in Chile, India, Mexico, Russia, South Korea, 
and Taiwan between November 2011 and June 2012. Results: Because hepatitis A 
is more of a concern during periods of economic transition for most countries, and 
because it is often perceived as a non-serious illness, countries struggle to align all 
of the factors necessary for adoption. Even where solid data exist, political support 
is often waning due to apparent transition to low endemicity for hepatitis A and a 
reduced threat. Where data are lacking, other vaccines take priority. Where economic 
studies exist, narrow perspectives fail to capture the broader threat of the disease to 
regional or country economies. Hepatitis A vaccination policy is further complicated 
by the fact that as countries transition to lower endemicity, the major threat is in older 
age groups. This trend leads to a subtle shift in stakeholders from the pediatric vaccine 
community to those more focused on the adult health community. ConClusions: 
Although the vaccine adoption process is the same for hepatitis A as for other pedi-
atric vaccines, this study suggests that drivers of hepatitis A vaccine adoption may 
come from sectors outside the traditional pediatric vaccine community.
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objeCtives: Vaccination constitutes a standard element of public health preventa-
tive programmes worldwide; however, majority tend to concentrate on early stages 
of life, limiting opportunity for other population groups (adolescents, adults and 
elderly) to fully benefit. The goal of this study was to uncover barriers underpin-
ning limited and inconsistent utilisation of vaccination at all stages of life (lifespan 
immunisation). Methods: Current access to vaccination was evaluated using pub-
lically available government websites in five market archetypes based on purchase 
and delivery mechanisms. A web-based survey and subsequent in-depth interviews 
were conducted with 22 country- and European-level vaccine stakeholders to iden-
tify perceived barriers. Results: Key barriers: constrained finance and compet-
ing health care priorities; policy decisions undertaken at disease level; national 
immunisation programme (NIP) recommendations based on age and risk; poor 
influence on policy by public health practitioners and lack of vaccination advocacy 
groups; constrained finances to implement effective immunisation programmes 
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for the FDA, EMA, Health Canada and Australia the Australian Therapeutic Goods 
Administration. The studies used to make regulatory decisions were then compared 
to the studies used in the reimbursement decisions of France, Scotland, Canada and 
Australia. Results: In all 15 cases reviewed the FDA, EMA and Health Canada used 
at least one of the same studies to come to their decision and in 13 of the cases 
Australia also used that same study. In 14 cases the FDA approved the drug before 
the other regulatory authorities; the longest time before another regulatory agency 
approved a drug was 15 months for rilpivirine. In six cases the FDA commissioned 
studies that other regulatory bodies and reimbursement agencies used later. All 
of the studies were interventional studies. Reimbursement agencies always used 
studies that were previously cited in regulatory documents. These agencies would 
also use studies intended for the regulatory approval of another drug as a source 
for information in a review. ConClusions: Reimbursement agencies and other 
regulatory agencies are influenced by the FDA in the studies they consider, as illus-
trated by at least six cases in which other agencies used studies commissioned by 
the FDA after approval. This influence is easier to see in the last five years, but may 
be older than that due to improvements in published reports.
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objeCtives: General practitioners (GPs) play an essential role in France in the 
prescription and administration of vaccines. Understanding factors that influence 
GPs’ opinions regarding vaccination would help improve vaccination rate in the 
general population. The study objectives were to understand and describe GPs’ 
attitudes, beliefs and behaviours regarding vaccination, to develop a self-report 
tool enabling characterisation of GPs, to assess the prevalence and determinants of 
vaccination behaviours and to identify the modifiable barriers regarding vaccina-
tion. Methods: Focus groups with French GPs (n= 36) were conducted following a 
semi-structured interview guide. Main themes of the guide were identified through 
a literature review. Qualitative analysis enabled development of a conceptual frame-
work based on the theory of planned behaviour (TPB). Items were then generated 
based on GPs’ quotations. Cognitive debriefing interviews with GPs (n= 10) were 
conducted to assess understanding, acceptability and content validity of the tool. 
Research methods and results were approved by a committee involving GPs, vac-
cination and tool development experts. Results: Focus groups revealed that GPs’ 
attitudes, beliefs and behaviours regarding vaccination varied depending on target 
disease and population. GPs were influenced by factors classified in 6 themes: vac-
cine characteristics, disease characteristics, practical aspects, expected benefits, 
personal background and relationship with patients. These qualitative findings 
supported item generation of the tool to capture 39 detailed concepts. The tool was 
developed to be generic for any disease that could be prevented by vaccination. 
Comprehension testing to confirm the relevance and understanding of the tool is 
underway. ConClusions: The tool was developed following rigorous methodology 
based on documented qualitative research. The TPB seems appropriate for organis-
ing qualitative research findings. Characterisation of GPs based on their attitudes, 
beliefs and behaviours regarding vaccination is expected to predict their intention 
to vaccinate and thus enable development of efficient programs promoting vac-
cination. The next step is to perform psychometric validation.
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objeCtives: It is assumed that agencies influence one another but little has 
been written on the extent of this influence. This analysis aims to explore how 
regulatory decisions affect reimbursement decisions within one HIV drug, daru-
navir. Methods: Documents from the FDA, European Public Assessment Report 
(EPAR), Health Canada, and the Australian Register of Therapeutic Goods together 
with the reimbursement decisions from France, Scotland, Canada and Australia were 
analyzed. The clinical trials found in these documents were compared. Results: 
The FDA approved darunavir ethanolate on June 23, 2006 based on the POWER 1, 2 
and 3 clinical trials. After approval, the FDA also required further reports (to be com-
pleted by December 31, 2007) on two Phase III studies, ARTEMIS and TITAN. Health 
Canada approved darunavir on July 28, 2006 and used the POWER studies along 
with the ARTEMIS and TITAN studies in its decision. The EMA approved darunavir 
on December 2, 2007 but gave conditional authorization a year earlier. EPAR also 
used the TITAN and POWER studies to make its decision. The French reimbursement 
agency used the ARTEMIS and TITAN studies in two recommendations. Scotland 
and Canada cited the ARTEMIS study in their recommendations. Australia used the 
POWER and TITAN studies in two recommendations and the ARTEMIS study in its 
one negative recommendation, citing an inappropriate comparator for the popula-
tion under review. ConClusions: Studies that required further review by the FDA 
after approval were key in determining regulatory decisions by Health Canada, 
EMA and Australia. The reimbursement decisions of France, Scotland, Canada and 
Australia also relied on these commissioned studies.
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chronic (e.g., diabetes, hypercholesterolemia, schizophrenia) rather than life-threat-
ening and that treatments, while costly, lead to significant savings in medical ben-
efits and ultimately leave medication decisions to specialists. Payers are cautiously 
examining potential savings and were willing to institute modest management for 
generics (tier 1) while keeping branded FDCs on preferred tier 2 (branded preferred 
copay). Payers were unwilling to institute, high cost-sharing co-insurance, prior 
authorizations, or require failure for members to access branded HIV medications 
presently or in the near future. ConClusions: Payers recognize the complexity 
of treating HIV, the role of adherence, the high cost of failure and the public health 
component of preventing resistance. We found payers to cautiously look at potential 
cost savings in medication management until all FDC components become generic. 
We found no widespread desire to drive generic adoption in HIV treatment, and little 
interest in the “de-simplification” of currently available FDCs.
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objeCtives: Inadequate or partial treatment of Tuberculosis (TB) is a known factor 
that would promote drug resistance, thus increasing the overall cost of TB manage-
ment. The study objectives are to identify the general characteristics of defaulting 
patients and to estimate the cost impact on health authorities as compared to non-
defaulters. Methods: A retrospective case-control study was carried out in public 
treatment centres in Selangor, Malaysia. Defaulter is defined as TB patient who has 
interrupted treatment for two consecutive months or more and did not complete 
their treatment. All subjects were selected from 2011 TB District Registry database. 
Patients’ medical case notes and baseline characteristics were reviewed and analysed. 
The direct costs of TB management were estimated from public health cost refer-
ences. The study was performed from a government’s perspective. Results: A total 
of 176 defaulters and 204 non-defaulters were studied. Foreign-born patients showed 
a higher risk (OR= 5.929; p < 0.01) of defaulting treatment. Unemployed patients were 
also more likely to default treatment (OR= 1.521 p> 0.05). Defaulters were more likely 
to default treatment during intensive phase as compared to maintenance phase 
(68.1% vs. 31.9%; p< 0.05). No other significant findings were observed between the 
two groups including age, ethnicity, severity of x-ray changes, type of TB and overall 
medical risk factors. Mean cost of the non-defaulter group is higher than the defaulter 
group due to a complete treatment (RM 1,259.62 vs. RM 575.58; p< 0.05). No significant 
treatment cost difference was observed in foreign-born defaulters as compared to 
local Malaysians (mean: RM 576.43 vs. RM 573.78; p> 0.05). ConClusions: Data from 
this study suggest TB treatment should be completed to avoid a potential huge waste 
of resources. More attentions are required for foreign-born defaulters due to over-
all consequence in public health and management cost. Additional costs would be 
required if susceptible TB strains of the defaulters turned into more virulent strains.
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objeCtives: To describe the burden of influenza for children and adults diagnosed 
with seasonal influenza in Germany. Methods: The study was based on a retro-
spective database analysis, using a longitudinal electronic medical records database 
(IMS® Disease Analyzer). Patients with influenza episodes (ICD-10 diagnosis J09-
11) being observable 12 months before index date and 1 month afterwards were 
included. The selection window was May 2010 to April 2012 to cover two influenza 
seasons. Results: A total of 23,068 influenza episodes (19,446 patients) managed 
by primary care practitioners (PCP) and 7,295 episodes (5,988 patients) managed by 
pediatricians were eligible. Mean age of patients was 43±20 years in the PCP panel 
and 7±4 years in the pediatrician panel. The presence of clinical risk factors was 
documented for 40% of episodes in adults and 31% of episodes in children. The most 
common risk factors were cardiovascular diseases in adults (28%) and chronic res-
piratory diseases in children (26%). The presence of risk factors correlated with the 
number of episodes/patient. Influenza episodes were frequently accompanied by 
complications (adults: 38%; children: 57%). Bronchitis (adults: 16%, children: 20%) 
and acute upper respiratory infections (adults: 15%, children: 21%) accounted for the 
most frequent complications. Mean number of physician visits was 1.2± 0.5 in adults 
and 1.5±0.8 in children. Nevertheless one in three children (34%) had more than one 
visit/episode due to complications. About 60% of episodes (adults: 60%; children: 64%) 
with at least one complication were reported in patients without risk factors. About 
50% of patients received drug prescriptions related either to influenza diagnosis or 
complications. ConClusions: This study demonstrates that in Germany seasonal 
influenza is associated with a substantial disease burden and considerable resource 
utilization, which can be preventable by vaccination. The findings may suggest the 
modification of the current vaccination recommendation for at risk populations.
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objeCtives: This analysis compares the studies that four regulatory agencies used 
to make their decisions and compares the relationship between the reasons for 
regulatory decisions and reasons for reimbursement decisions. Methods: The 
scientific discussions and the studies used to make regulatory decisions for 15 
different HIV drugs approved over the last 12 years (2000-2012) were compared 
